SAB Biotherapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
SABS$3.07-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes In Stockholders’ Equity
(in thousands, except par value and share amounts) (Unaudited)
| Common stock · Series B Preferred Stock · Series A Preferred Stock · Treasury Stock | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | AdditionalPaid-In Capital | Shares | Amount | AccumulatedDeficit | Accumulated Other Comprehensive Income (Loss) | Total Stockholders’Equity | |
| Balance at December 31, 2025 | 47,664,564 | $5 | 638,558 | $— | 28,380 | $— | $267,719 | (54,665) | $(5,521) | $(110,895) | $187 | $151,495 |
| Stock-based compensation | — | — | — | — | — | — | 5,460 | — | — | — | — | 5,460 |
| Issuance of common stock under equity plan, net of shares withheld for taxes | 42,100 | — | — | — | — | — | 108 | — | — | — | — | 108 |
| Conversion of Series B Preferred Stock into common shares | 6,767,900 | 1 | (67,679) | — | — | — | (1) | — | — | — | — | — |
| Exercise of Enrollment Date Warrants into Series B Preferred Stock | — | — | 17,000 | — | — | — | 2,975 | — | — | — | — | 2,975 |
| Issuance of common stock and pre-funded warrants in the March 2026 Public Offering, including the underwriters' option, net of issuance costs | 21,324,677 | 2 | — | — | — | — | 86,487 | — | — | — | — | 86,489 |
| Net loss | — | — | — | — | — | — | — | — | — | (18,869) | — | (18,869) |
| Foreign currency translation | — | — | — | — | — | — | — | — | — | — | 137 | 137 |
| Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment | — | — | — | — | — | — | — | — | — | — | (547) | (547) |
| Balance at March 31, 2026 | 75,799,241 | $8 | 587,879 | $— | 28,380 | $— | $362,748 | (54,665) | $(5,521) | $(129,764) | $(223) | $227,248 |
| Stock-based compensation | — | — | — | — | — | — | 7,247 | — | — | — | — | 7,247 |
| Issuance of common stock under equity plan, net of shares withheld for taxes | 28,016 | — | — | — | — | — | 38 | — | — | — | — | 38 |
| Conversion of Series B Preferred Stock into common shares | 7,035,000 | — | (70,350) | — | — | — | — | — | — | — | — | — |
| Exercise of Enrollment Date and Release Date Warrants into Series B Preferred Stock | — | — | 5,100 | — | — | — | 981 | — | — | — | — | 981 |
| Issuance of common stock under the March 2026 Public Offering Underwriters' Option, net of issuance costs | 610,188 | — | — | — | — | — | 2,208 | — | — | — | — | 2,208 |
| Issuance of common stock as consideration for professional services | 75,288 | — | — | — | — | — | 261 | — | — | — | — | 261 |
| Net loss | — | — | — | — | — | — | — | — | — | (22,491) | — | (22,491) |
| Foreign currency translation | — | — | — | — | — | — | — | — | — | — | 10 | 10 |
| Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment | — | — | — | — | — | — | — | — | — | — | (717) | (717) |
| Balance at June 30, 2026 | 83,547,733 | $8 | 522,629 | $— | 28,380 | $— | $373,483 | (54,665) | $(5,521) | $(152,255) | $(930) | $214,785 |
| Stock-based compensation | — | — | — | — | — | — | 7,437 | — | — | — | — | 7,437 |
| Issuance of common stock under equity plan, net of shares withheld for taxes | 1,655 | — | — | — | — | — | (1) | — | — | — | — | (1) |
| Conversion of Series B Preferred Stock into common shares | 7,643,300 | 1 | (76,433) | — | — | — | (1) | — | — | — | — | — |
| Exercise of Enrollment Date and Release Date Warrants into Series B Preferred Stock | — | — | 76,433 | — | — | — | 12,378 | — | — | — | — | 12,378 |
| Issuance costs related to the March 2026 Public Offering | — | — | — | — | — | — | (5) | — | — | — | — | (5) |
| Net loss | — | — | — | — | — | — | — | — | — | (22,300) | — | (22,300) |
| Foreign currency translation | — | — | — | — | — | — | — | — | — | — | 41 | 41 |
| Unrealized loss, change in fair value of available-for-sale securities, net of reclassification adjustment | — | — | — | — | — | — | — | — | — | — | (1,414) | (1,414) |
| Balance at September 30, 2026 | 91,192,688 | $9 | 522,629 | $— | 28,380 | $— | $393,291 | (54,665) | $(5,521) | $(174,555) | $(2,303) | $210,921 |
Condensed Consolidated Statements of Changes In Stockholders’ Equity
(in thousands, except par value and share amounts)
| Common stock · Series B Preferred Stock · Series A Preferred Stock · Treasury Stock | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | AdditionalPaid-In Capital | Shares | Amount | AccumulatedDeficit | Accumulated Other Comprehensive Income (Loss) | Total Stockholders’Equity | |
| Balance at December 31, 2024 | 9,343,533 | $1 | — | $— | 42,019 | $— | $155,794 | (54,665) | $(5,521) | $(124,169) | $(135) | $25,970 |
| Stock-based compensation | — | — | — | — | — | — | 613 | — | — | — | — | 613 |
| Issuance of common stock pursuant to vesting of restricted stock units | 2,829 | — | — | — | — | — | — | — | — | — | — | — |
| Payment of taxes withheld on issuance of restricted stock units | — | — | — | — | — | — | (2) | — | — | — | — | (2) |
| Net loss | — | — | — | — | — | — | — | — | — | (5,197) | — | (5,197) |
| Foreign currency translation | — | — | — | — | — | — | — | — | — | — | 25 | 25 |
| Unrealized loss, change in fair value of available-for-sale securities | — | — | — | — | — | — | — | — | — | — | (1) | (1) |
| Balance at March 31, 2025 | 9,346,362 | $1 | — | $— | 42,019 | $— | $156,405 | (54,665) | $(5,521) | $(129,366) | $(111) | $21,408 |
| Stock-based compensation | — | — | — | — | — | — | 627 | — | — | — | — | 627 |
| Net loss | — | — | — | — | — | — | — | — | — | (10,114) | — | (10,114) |
| Foreign currency translation | — | — | — | — | — | — | — | — | — | — | 95 | 95 |
| Unrealized gain, change in fair value of available-for-sale securities | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance at June 30, 2025 | 9,346,362 | $1 | — | $— | 42,019 | $— | $157,032 | (54,665) | $(5,521) | $(139,480) | $(16) | $12,016 |
| Stock-based compensation | — | — | — | — | — | — | 801 | — | — | — | — | 801 |
| Conversion of Series A Preferred Stock into common shares | 2,052,061 | — | — | — | (12,928) | — | — | — | — | — | — | — |
| Issuance of Series B Preferred Stock and warrants under private placement offering | — | — | — | — | — | — | — | — | — | — | — | — |
| Reclassification of Redeemable Preferred Stock to Permanent Equity upon Requisite Approval | — | — | 1,000,000 | — | — | — | 16,039 | — | — | — | — | 16,039 |
| Conversion of Series B Preferred Stock into common shares | 36,144,200 | 4 | (361,442) | — | — | — | (4) | — | — | — | — | — |
| Reclassification of PIPE Warrants to Permanent Equity following shareholder approval | — | — | — | — | — | — | 90,691 | — | — | — | — | 90,691 |
| Issuance of common stock pursuant to vesting of restricted stock units | 6,036 | — | — | — | — | — | — | — | — | — | — | — |
| Payment of taxes withheld on issuance of restricted stock units | — | — | — | — | — | — | (5) | — | — | — | — | (5) |
| Net income | — | — | — | — | — | — | — | — | — | 45,445 | — | 45,445 |
| Foreign currency translation | — | — | — | — | — | — | — | — | — | — | (1) | (1) |
| Unrealized gain, change in fair value of available-for-sale securities | — | — | — | — | — | — | — | — | — | — | 88 | 88 |
| Balance at September 30, 2025 | 47,548,659 | $5 | 638,558 | $— | 29,091 | $— | $264,554 | (54,665) | $(5,521) | $(94,035) | $71 | $165,074 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.